Payment overview · 2025
General Payments
$439.89
7 reported records · 4 companies
Healthcare provider profile · identity verified
Carlos M Delgado, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HORMIGUEROS, PR · NPI 1912112749
Verified facts
What the public records show
CMS Open Payments records show Carlos M Delgado, M.D. received $439.89 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Lokelma.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.77 | 42.2% | 3 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $122.55 | 27.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $75.00 | 17.1% | 1 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $56.57 | 12.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.89 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $122.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.38 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $75.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Puerto Rico Inc. | $56.57 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.36 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $51.36 | 1 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $51.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 148 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
80 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
148 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 826 | 156 |
| Atorvastatin Calcium | Atorvastatin Calcium | 561 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 561 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 517 | 110 |
| Losartan Potassium | Losartan Potassium | 483 | 157 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 152 |
| Famotidine | Famotidine | 436 | 113 |
| Synthroid | Levothyroxine Sodium | 427 | 59 |
| Montelukast Sodium | Montelukast Sodium | 357 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 117 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 59 |
| Omeprazole | Omeprazole | 282 | 57 |
| Doxazosin Mesylate | Doxazosin Mesylate | 278 | 91 |
| Alendronate Sodium | Alendronate Sodium | 274 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 93 |
| Clopidogrel | Clopidogrel Bisulfate | 232 | 96 |
| Metformin Hcl | Metformin Hcl | 217 | 79 |
| Meloxicam | Meloxicam | 208 | 47 |
| Carvedilol | Carvedilol | 205 | 75 |
| Simvastatin | Simvastatin | 199 | 59 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 188 | 72 |
| Ezetimibe | Ezetimibe | 185 | 80 |
| Sertraline Hcl | Sertraline Hcl | 177 | 31 |
| Finasteride | Finasteride | 176 | 41 |
| Lansoprazole | Lansoprazole | 164 | 37 |
| Lisinopril | Lisinopril | 156 | 67 |
| Enalapril Maleate | Enalapril Maleate | 150 | 42 |
| Farxiga | Dapagliflozin Propanediol | 148 | 50 |
| Glimepiride | Glimepiride | 145 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 22 |
| Eliquis | Apixaban | 135 | 42 |
| Donepezil Hcl | Donepezil Hcl | 128 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 127 | 19 |
| Mirtazapine | Mirtazapine | 123 | 24 |
| Clonazepam | Clonazepam | 116 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 35 |
| Alprazolam | Alprazolam | 108 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 108 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 15 |
| Xarelto | Rivaroxaban | 104 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 103 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 36 |
| Bumetanide | Bumetanide | 99 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 95 | 31 |
| Furosemide | Furosemide | 87 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 35 |
| Trazodone Hcl | Trazodone Hcl | 84 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 29 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 82 | 33 |
| Brilinta | Ticagrelor | 80 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 34 |
| Levofloxacin | Levofloxacin | 79 | 74 |
| Nitroglycerin | Nitroglycerin | 79 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 37 |
| Spironolactone | Spironolactone | 74 | 37 |
| Naproxen | Naproxen | 72 | 22 |
| Fenofibrate | Fenofibrate | 68 | 19 |
| Sucralfate | Sucralfate | 65 | 17 |
| Lorazepam | Lorazepam | 63 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 18 |
| Glipizide | Glipizide | 58 | 24 |
| Memantine Hcl | Memantine Hcl | 54 | 13 |
| Humalog | Insulin Lispro | 52 | 21 |
| Candesartan Cilexetil | Candesartan Cilexetil | 51 | 26 |
| Cilostazol | Cilostazol | 51 | 15 |
| Nifedipine Er | Nifedipine | 48 | 25 |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 13 |
| Latanoprost | Latanoprost | 45 | 12 |
| Nabumetone | Nabumetone | 45 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 20 |
| Irbesartan | Irbesartan | 43 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | suppressed |
| Allopurinol | Allopurinol | 40 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 35 |
| Prednisone | Prednisone | 39 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 14 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 13 |
| Verapamil Er | Verapamil Hcl | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Insulin Lispro | Insulin Lispro | 30 | 17 |
| Lactulose | Lactulose | 30 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 28 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 11 |
| Diclofenac Potassium | Diclofenac Potassium | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | 11 |
| Humulin R | Insulin Regular, Human | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Lumigan | Bimatoprost | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Sulindac | Sulindac | 22 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Advocate Syringes | Syring-Needl,disp,insul,0.3 Ml | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Levoxyl | Levothyroxine Sodium | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Levo-T | Levothyroxine Sodium | 14 | suppressed |
| Piroxicam | Piroxicam | 14 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | 11 |
| Fluconazole | Fluconazole | 12 | 11 |
| Letrozole | Letrozole | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Trileptal | Oxcarbazepine | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.89 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, Fetroja, Kerendia, LOKELMA, LUX-Dx Insertable Cardiac Monitor, NEXIUM | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error